HK1207068A1 - 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) - Google Patents

3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)

Info

Publication number
HK1207068A1
HK1207068A1 HK15107643.9A HK15107643A HK1207068A1 HK 1207068 A1 HK1207068 A1 HK 1207068A1 HK 15107643 A HK15107643 A HK 15107643A HK 1207068 A1 HK1207068 A1 HK 1207068A1
Authority
HK
Hong Kong
Prior art keywords
1h4h6h
pyrrolo
pyrazole
amido
inhibitors
Prior art date
Application number
HK15107643.9A
Other languages
English (en)
Chinese (zh)
Inventor
‧伯特魯斯
洪玉峰
李輝
‧劉
貫井齊治
滕敏
‧湯普金斯
尹春風
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1207068A1 publication Critical patent/HK1207068A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK15107643.9A 2007-04-12 2010-06-09 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h) HK1207068A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91146207P 2007-04-12 2007-04-12
US3551908P 2008-03-11 2008-03-11
US4011508P 2008-03-27 2008-03-27

Publications (1)

Publication Number Publication Date
HK1207068A1 true HK1207068A1 (en) 2016-01-22

Family

ID=39764996

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107642.0A HK1207067A1 (en) 2007-04-12 2010-06-09 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)
HK15107643.9A HK1207068A1 (en) 2007-04-12 2010-06-09 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15107642.0A HK1207067A1 (en) 2007-04-12 2010-06-09 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)

Country Status (11)

Country Link
US (2) US8114871B2 (xx)
EP (1) EP2195321B1 (xx)
JP (1) JP5404601B2 (xx)
KR (1) KR101113387B1 (xx)
CN (3) CN104370914B (xx)
AU (1) AU2008237660B2 (xx)
CA (1) CA2683695C (xx)
HK (2) HK1207067A1 (xx)
IL (1) IL201104A (xx)
MX (1) MX2009010951A (xx)
WO (1) WO2008125945A2 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
WO2011044264A2 (en) * 2009-10-06 2011-04-14 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
GEP20146169B (en) * 2009-11-10 2014-09-25 Pfizer N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
ES2602111T3 (es) 2010-09-30 2017-02-17 Pfizer Inc Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona
MX2013004733A (es) 2010-10-29 2013-07-02 Pfizer Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
AU2012214405B2 (en) 2011-02-11 2015-07-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
MA35061B1 (fr) 2011-04-22 2014-04-03 Pfizer Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013038390A1 (en) * 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2847191B1 (en) 2012-05-09 2016-06-15 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
CN105377852B (zh) 2014-05-23 2018-08-28 深圳明赛瑞霖药业有限公司 自身免疫疾病的治疗
US10131679B2 (en) * 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
WO2016081311A1 (en) * 2014-11-21 2016-05-26 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10273252B2 (en) 2015-06-15 2019-04-30 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3376869B1 (en) 2015-11-20 2022-01-05 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
WO2018013862A1 (en) 2016-07-14 2018-01-18 Mingsight Pharmaceuticals, Inc. Treatment of cancer
US20220002303A1 (en) 2018-11-14 2022-01-06 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229824B1 (en) * 2000-08-10 2014-08-28 Pfizer Italia Srl Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US20070037790A1 (en) * 2003-03-11 2007-02-15 Francesca Abrate Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005030776A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
AU2005323797B2 (en) * 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体

Also Published As

Publication number Publication date
EP2195321B1 (en) 2016-10-19
AU2008237660A1 (en) 2008-10-23
US20100249128A1 (en) 2010-09-30
KR20090130039A (ko) 2009-12-17
KR101113387B1 (ko) 2012-04-23
US8114871B2 (en) 2012-02-14
CA2683695C (en) 2013-06-18
CN101675052A (zh) 2010-03-17
IL201104A (en) 2017-09-28
IL201104A0 (en) 2010-05-17
US8999981B2 (en) 2015-04-07
EP2195321A2 (en) 2010-06-16
CN104370914A (zh) 2015-02-25
JP5404601B2 (ja) 2014-02-05
HK1207067A1 (en) 2016-01-22
US20120108588A1 (en) 2012-05-03
WO2008125945A3 (en) 2009-03-12
JP2010523643A (ja) 2010-07-15
WO2008125945A2 (en) 2008-10-23
AU2008237660B2 (en) 2011-12-22
CN104370914B (zh) 2018-09-07
CN104356136A (zh) 2015-02-18
MX2009010951A (es) 2009-10-29
CA2683695A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
HK1207068A1 (en) 3-amido-pyrrolo [3,4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c c 3--[34-c]-5(1h4h6h)
HK1139130A1 (en) 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors pkc 3--[34-c]-5(1h4h6h)
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
ZA201002318B (en) Pyrrolo [2,3-d]pyrimidin derivatives as protein kinase b inhibitors
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
HK1126758A1 (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
ZA201003050B (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
IL217798A0 (en) Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
ZA201000627B (en) 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro-1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
ZA200907825B (en) 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
IL178688A0 (en) THIENO [3,2-b] PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS